Health Care

ANKARA, Türkei, June 18, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, ein globaler Pharmadienstleister, gab heute die Übernahme von Corena Ecza Deposu, dem führenden Pharmadistributor in der Türkei, bekannt und stärkt damit seine Position als einer der größten Dienstleister für den Life-Science-Sektor in der Türkei.

Excellent Brain Ltd. Expands Global Reach with Spanish Neurofeedback Course

Aliso Viejo, CA , June 18, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., developer of the Life Backup Plan digital health platform, proudly announces its advancement to the second round of Pepperdine University’s Most Fundable Companies® 2025 competition. The company earned a “B” rating, reflecting “Great Potential” among a competitive national pool of startups evaluated for scalability, business fundamentals, and investor appeal.

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.